Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

The ‘wildtype’ conformation of p53: epitope mapping using hybrid proteins

An Erratum to this article was published on 25 October 2001

Abstract

The function of p53 correlates with its ‘wildtype’ conformation, specifically recognized by antibodies PAb1620 and PAb246, and many cancer-associated mutations cause loss of this conformation. The epitopes of these antibodies were identified using hybrid p53 proteins created by a new method. Plasmids carrying homologous genes cut at appropriate sites recombined efficiently when transformed into RecE+ E. coli. PAb1620 and PAb246 recognize mouse but not chicken p53; we created mouse–chicken hybrids of the p53 core domain and tested antibody reactivity. PAb246 binding mapped to residues 201–212, while PAb1620 required both residues 145–157 and 201–212 (human p53 numbering used throughout). An alanine-scan showed that the key residues for PAb246 and PAb1620 are completely distinct: PAb246 recognizes residues 202–204 (Tyr-Pro-Glu) while PAb1620 recognizes residues Arg156, Leu206, Arg209, and Gln/Asn210, the last two residues being essential. Both antibody epitopes are far from the p53 interface with DNA, but near the epitope of the ‘mutant’ conformation antibody PAb240. These epitope locations may help in dissecting the interactions of p53, including those with E6/E6-AP and in its DNA-bound state.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Balagurumoorthy P, Sakamoto H, Lewis MS, Zambrano N, Clore GM, Gronenborn AM, Appella E, Harrington RE . 1995 Proc. Natl. Acad. Sci. USA 92: 8591–8595

  • Ball RK, Siegl B, Quellhorst S, Brandner G, Braun DG . 1984 EMBO J. 3: 1485–1491

  • Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR . 1997 Proc. Natl. Acad. Sci. USA 94: 14338–14342

  • Cho Y, Gorina S, Jeffrey PD, Pavletich NP . 1994 Science 265: 346–355

  • Chung CT, Niemela SL, Miller RH . 1989 Proc. Natl. Acad. Sci. USA 86: 2172–2175

  • Cohen PA, Hupp TR, Lane DP, Daniels DA . 1999 FEBS Lett. 463: 179–184

  • Cook A, Milner J . 1990 Br. J. Cancer 61: 548–552

  • Foster BA, Coffey HA, Morin MJ, Rastinejad F . 1999 Science 286: 2507–2510

  • Gannon JV, Greaves R, Iggo R, Lane DP . 1990 EMBO J. 9: 1595–1602

  • Gillen JR, Willis DK, Clark AJ . 1981 J. Bacteriol. 145: 521–532

  • Gorina S, Pavletich NP . 1996 Science 274: 1001–1005

  • Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC, Montesano R . 1998 Nucleic Acids Res. 26: 205–213

  • Halazonetis TD, Davis LJ, Kandil AN . 1993 EMBO J. 12: 1021–1028

  • Halazonetis TD, Kandil AN . 1993 EMBO J. 12: 5057–5064

  • Hall AR, Milner J . 1995 Oncogene 10: 561–567

  • Hansen S, Lane DP, Midgley CA . 1998 J. Mol. Biol. 275: 575–588

  • Huibregtse JM, Scheffner M, Howley PM . 1991 EMBO J. 10: 4129–4135

  • Hupp TR, Meek DW, Midgley CA, Lane DP . 1992 Cell 71: 875–886

  • Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D . 1997 Cell 90: 809–819

  • Kolodner R, Hall SD, Luisi-DeLuca C . 1994 Mol. Microbiol. 11: 23–30

  • Kraulis PJ . 1991 J. Applied Crystallog. 24: 946–950

  • Lane DP, Stephen CW, Midgley CA, Sparks A, Hupp TR, Daniels DA, Greaves R, Reid A, Vojtesek B, Picksley SM . 1996 Oncogene 12: 2461–2466

  • Legros Y, Lafon C, Soussi T . 1994a Oncogene 9: 2071–2076

  • Legros Y, Meyer A, Ory K, Soussi T . 1994b Oncogene 9: 3689–3694

  • Levine AJ . 1997 Cell 88: 323–331

  • Li X, Coffino P . 1996a J. Virol. 70: 4509–4516

  • Li X, Coffino P . 1996b J. Biol. Chem. 271: 4447–4451

  • McLure KG, Lee PW . 1996 Oncogene 13: 1297–1303

  • Medcalf EA, Milner J . 1993 Oncogene 8: 2847–2851

  • Merritt EA, Murphy MEP . 1994 Acta Crystallographica Section D 50: 869–873

  • Milner J, Cook A, Sheldon M . 1987 Oncogene 1: 453–455

  • Molinari M, Milner J . 1995 Oncogene 10: 1849–1854

  • Müller-Tiemann BF, Halazonetis TD, Elting JJ . 1998 Proc. Natl. Acad. Sci. USA 95: 6079–6084

  • Ravera MW, Carcamo J, Brissette R, Alam-Moghe A, Dedova O, Cheng W, Hsiao KC, Klebanov D, Shen H, Tang P, Blume A, Mandecki W . 1998 Oncogene 16: 1993–1999

  • Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM . 1990 Cell 63: 1129–1136

  • Soussi T, May P . 1996 J. Mol. Biol. 260: 623–637

  • Stephen CW, Lane DP . 1992 J. Mol. Biol. 225: 577–583

  • Stürzbecher H-W, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E, Jenkins JR . 1992 Oncogene 7: 1513–1523

  • Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA, Lane DP . 1995 Oncogene 10: 389–393

  • Wade-Evans A, Jenkins JR . 1985 EMBO J. 4: 699–706

  • Wang PL . 2001 Disease Markers 16

  • Wang Y, Schwedes JF, Parks D, Mann K, Tegtmeyer P . 1995 Mol. Cell. Biol. 15: 2157–2165

  • Wolkowicz R, Elkind NB, Ronen D, Rotter V . 1995 Oncogene 10: 1167–1174

  • Yewdell JW, Gannon JV, Lane DP . 1986 J. Virol. 59: 444–452

Download references

Acknowledgements

We thank Alex Bullock, Penka Nikolova, and Alan Fersht for purified human p53 core domain protein, DNA, and MAbs; and Carol Midgley, Sylvain Arnould, and Penka Nikolova for critical reading of the manuscript. PL Wang was supported by a Hitchings-Elion fellowship from the Burroughs-Wellcome Fund and by the Medical Research Council.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, P., Sait, F. & Winter, G. The ‘wildtype’ conformation of p53: epitope mapping using hybrid proteins. Oncogene 20, 2318–2324 (2001). https://doi.org/10.1038/sj.onc.1204316

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204316

Keywords

This article is cited by

Search

Quick links